<DOC>
	<DOCNO>NCT00063934</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose oblimersen give together doxorubicin docetaxel see well work treat woman metastatic locally advanced breast cancer . Drugs use chemotherapy , doxorubicin docetaxel , work different way stop tumor cell divide stop grow die . Oblimersen may increase effectiveness doxorubicin docetaxel make tumor cell sensitive drug .</brief_summary>
	<brief_title>Oblimersen Plus Doxorubicin Docetaxel Treating Patients With Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate pharmacokinetics G3139 , doxorubicin docetaxel breast cancer patient receive G3139/AT therapy . ( Phase I ) II . To determine safety bcl-2 antisense oligonucleotide G3139 ( GenasenseTM ) together docetaxel plus doxorubicin ( AT ) patient metastatic locally advanced breast cancer ( LABC ) . ( Phase I ) III . To determine therapeutic efficacy neoadjuvant G3139 combination AT chemotherapy patient LABC . ( Phase II ) IV . To evaluate safety bcl-2 antisense oligonucleotide G3139 ( GenasenseTM ) together docetaxel plus doxorubicin ( AT ) patient locally advance breast cancer ( LABC ) . ( Phase II ) SECONDARY OBJECTIVES : I . To determine clinical image response neoadjuvant G3139/AT breast axillary lymph node . ( Phase II ) II . To determine disease-free survival breast cancer patient treat neoadjuvant G3139/AT . ( Phase II ) III . To define pharmacokinetics G3139/AT . ( Phase II ) IV . To evaluate role Bcl-2 expression predictor response neoadjuvant G3139/AT therapy . ( Phase II ) V. To obtain serial breast cancer sample patient treat G3139 . ( Phase II ) OUTLINE : This open-label , dose-escalation study oblimersen . PHASE I ( COMPLETED AS OF 8/16/04 ) : Patients receive oblimersen IV continuously day 1-6 interrupted administer doxorubicin IV 15 minute docetaxel IV 60 minute day 6 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) day 7-13 pegfilgrastim SC day 7 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PHASE II : Patients receive doxorubicin , docetaxel , G-CSF pegfilgrastim , oblimersen MTD phase I . Patients resectable tumor 6 course undergo surgical resection . Patients follow every 3-6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>PHASE I : Patients must histologically cytologically confirm breast cancer PHASE I : To eligible phase I component study , patient must stage IIIB , IIIC IV breast cancer ; include patient T4 , N , M0 ; T , N3 , M0 ; T , N , M1 PHASE I : Measurable disease require patient participate phase I component PHASE I : Prior G3139 , taxane anthracycline therapy allow PHASE I : Patients may receive 3 prior chemotherapy regimen breast cancer ( exclude anthracyclines taxanes ) , either adjuvant/neoadjuvant therapy metastatic disease PHASE I : Life expectancy great 6 month PHASE I : ECOG performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) PHASE I : Leukocytes &gt; = 3,000/L PHASE I : Absolute neutrophil count &gt; = 1,500/L PHASE I : Platelets &gt; = 100,000/L PHASE I : Total bilirubin = &lt; 1.5 mg/dl PHASE I : ALT ( SGPT ) = &lt; 2.5 X upper limit normal PHASE I : Creatinine = &lt; 2.0 mg/dl PHASE I : Normal cardiac function ( LVEF &gt; = 45 % ) document MUGA scan and/or echocardiogram PHASE I : The effect G3139 develop human fetus recommend therapeutic dose unknown ; reason anthracycline taxanes use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately PHASE I : Ability understand willingness sign write informed consent document PHASE II : Patients must histologically cytologically confirm breast cancer PHASE II : Patients must stage IIIA , IIIB , IIIC breast cancer ; include patient T4 , N , M0 ; T , N23 , M0 ; T3 , N1 , M0 ; patient ipsilateral supraclavicular lymph node metastasis ( IIIC ) eligible ; patient evidence distant metastasis ( stage IV ) eligible PHASE II : Measurable disease require ; disease measure prior initiation G3139/doxorubicin/docetaxel therapy physical exam , mammography ultrasound affect area ; pathologic response measure time definitive surgery PHASE II : Prior G3139 therapy allow PHASE II : Prior chemotherapy , hormone therapy , definitive surgery , radiation therapy breast cancer allow PHASE II : Life expectancy great 6 month PHASE II : ECOG performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) PHASE II : Leukocytes &gt; = 3,000/L PHASE II : Absolute neutrophil count &gt; = 1,500/L PHASE II : Platelets &gt; = 100,000/L PHASE II : Total bilirubin = &lt; 1.5 mg/dl PHASE II : ALT ( SGPT ) = &lt; 2.5 X upper limit normal PHASE II : Creatinine = &lt; 2.0 mg/dl PHASE II : Normal cardiac function ( LVEF &gt; = 45 % ) document MUGA scan and/or echocardiogram PHASE II : The effect G3139 develop human fetus recommend therapeutic dose unknown ; reason anthracycline taxanes use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately PHASE II : Ability understand willingness sign write informed consent document PHASE I : Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter phase I study recovered adverse event due agent administer 4 week earlier PHASE I : Patients may receive investigational agent PHASE I : Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event PHASE I : Leptomeningeal disease PHASE I : Symptomatic lymphangitic pulmonary metastasis PHASE I : History allergic reaction attribute compound similar chemical biologic composition G3139 agent use study ; patient exclude know hypersensitivity drug formulate polysorbate 80 ( Tween 80 ) PHASE I : Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement PHASE I : Patients neuropathy grade 2 high PHASE I : Pregnant woman exclude study G3139 oligonucleotide agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother G3139 , breastfeed discontinue mother treated G3139 ; potential risk may also apply agent use study , doxorubicin docetaxel PHASE II : Patients may receive investigational agent PHASE II : History allergic reaction attribute compound similar chemical biologic composition G3139 agent use study ; patient exclude know hypersensitivity drug formulate polysorbate 80 ( Tween 80 ) PHASE II : Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement PHASE II : Patients neuropathy grade 2 high PHASE II : Pregnant woman exclude study G3139 oligonucleotide agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother G3139 , breastfeed discontinue mother treated G3139 ; potential risk may also apply agent use study , doxorubicin docetaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>